Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …
understanding of disease biology and the identification of oncogenic driver alterations has …
[HTML][HTML] The current state of the art and future trends in RAS-targeted cancer therapies
SR Punekar, V Velcheti, BG Neel… - Nature reviews Clinical …, 2022 - nature.com
Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …
[HTML][HTML] A targetable CoQ-FSP1 axis drives ferroptosis-and radiation-resistance in KEAP1 inactive lung cancers
Targeting ferroptosis, a unique cell death modality triggered by unrestricted lipid
peroxidation, in cancer therapy is hindered by our incomplete understanding of ferroptosis …
peroxidation, in cancer therapy is hindered by our incomplete understanding of ferroptosis …
Diverse alterations associated with resistance to KRAS (G12C) inhibition
Y Zhao, YR Murciano-Goroff, JY Xue, A Ang, J Lucas… - Nature, 2021 - nature.com
Inactive state-selective KRAS (G12C) inhibitors,,,,,,–demonstrate a 30–40% response rate
and result in approximately 6-month median progression-free survival in patients with lung …
and result in approximately 6-month median progression-free survival in patients with lung …
[PDF][PDF] Proteogenomic characterization of pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …
survival. Toward understanding the underlying molecular alterations that drive PDAC …
[HTML][HTML] Detection and characterization of lung cancer using cell-free DNA fragmentomes
D Mathios, JS Johansen, S Cristiano, JE Medina… - Nature …, 2021 - nature.com
Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for
cancer detection and intervention. Here, we use a machine learning model for detecting …
cancer detection and intervention. Here, we use a machine learning model for detecting …
[HTML][HTML] Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
[HTML][HTML] Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to
import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in …
import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in …
[HTML][HTML] First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)
PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent
inhibitor of KRAS G12C. We report results from a phase I/IB study of adagrasib in non–small …
inhibitor of KRAS G12C. We report results from a phase I/IB study of adagrasib in non–small …